Factors influencing adverse events following COVID-19 vaccination.

Publication date: Dec 31, 2024

Various novel platform technologies have been used for the development of COVID-19 vaccines. In this nested cohort study among healthcare workers in Australia and Brazil who received three different COVID-19-specific vaccines, we (a) evaluated the incidence of adverse events following immunization (AEFI); (b) compared AEFI by vaccine type, dose and country; (c) identified factors influencing the incidence of AEFI; and (d) assessed the association between reactogenicity and vaccine anti-spike IgG antibody responses. Of 1302 participants who received homologous 2-dose regimens of ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac), 1219 (94%) completed vaccine reaction questionnaires. Following the first vaccine dose, the incidence of any systemic reaction was higher in ChAdOx1-S recipients (374/806, 46%) compared with BNT162b2 (55/151, 36%; pā€‰=ā€‰0. 02) or CoronaVac (26/262, 10%; pā€‰

Concepts Keywords
Astrazeneca adverse events
Australia antibody responses
Bnt162b2 COVID-19 vaccine


Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO immunization
disease VO vaccine
disease VO dose
disease IDO country
disease VO CoronaVac
disease VO vaccine dose
disease VO COVID-19 vaccine

Original Article

(Visited 1 times, 1 visits today)